St. Gabriel, 50
Esplugues de Llobregat
08950 Barcelona (Spain)
Pharmacovigilance Telephone (24/7)
+34 603 796 658
pharmacovigilance@galenicum.com
RESTRICTED ACCESS
The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.
The products mentioned may have a different authorized data sheet in each country.
If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.
DABIGAMAX
DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.